Home » Topics » Regulatory » EMA

EMA
RSS

FDA clears design of phase III oritavancin trials SOLO-1 and -2

Dec. 1, 2010

New Juvista formulation for children significantly improves scar appearance

Nov. 23, 2010

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Nov. 23, 2010

EMA's COMP recommends orphan status for paquinimod in systemic sclerosis

Nov. 18, 2010

EMA accepts Pixuvri MAA for non-Hodgkin's lymphoma for review

Nov. 18, 2010

Roche reports on third quarter of 2010

Nov. 18, 2010

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Nov. 17, 2010

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Nov. 17, 2010

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Nov. 12, 2010

Schering-Plough Europe withdraws MAA for Zenhale

Nov. 11, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...